Navigation Links
New Hope for Treatment of Pancreatic Cancer
Date:9/25/2009

By inhibiting key enzyme, researchers shrank tumors, prolonged survival in mice

FRIDAY, Sept. 25 (HealthDay News) -- Inhibiting the action of an enzyme called TAK-1 reverses pancreatic cancer resistance to chemotherapy, a finding that could lead to the development of a new way to treat the disease, researchers say.

Pancreatic cancer is resistant to every currently available anti-cancer treatment.

"During the past few years we have been studying the role played by a cytokine or regulatory protein called transforming growth factor-beta [TGFbeta] in the development of pancreatic cancer. Recently we focused our attention on a unique enzyme activated by TGFbeta, TAK-1, as a mediator for this extreme drug resistance" in pancreatic cancer, study author Dr. Davide Melisi said in a news release from the European Cancer Organization.

He and his colleagues developed a TAK-1 inhibitor and tested it on its own and in combination with the anti-cancer drugs gemcitabine, oxaliplatin and SN-38 (a metabolite of the anti-cancer drug irinotecan) in pancreatic cancer cell lines. They also tested the TAK-1 inhibitor combined with gemcitabine against pancreatic cancer in mice.

"The use of this TAK-1 inhibitor increased the sensitivity of pancreatic cells to all three chemotherapeutic drugs," Melisi said.

"By combining it with classic anti-cancer drugs, we were able to use doses of drugs up to 70 times lower in comparison with the control to kill the same number of cancer cells. In mice, we were able to reduce significantly the tumor volume, to prolong the mice survival, and to reduce the toxicity by combining the TAK-1 inhibitor with very low doses of a classic chemotherapeutic drug, gemcitabine, that would have been ineffective otherwise," Melisi added.

The study was scheduled for presentation Sept. 24 at the joint meeting of the European Cancer Organization and the European Society for Medical Oncology in Berlin.

"This is the first time that TAK-1 has been indicated as a relevant target for the treatment of a solid tumor and that it is a valid approach to reverting the intrinsic drug resistance of pancreatic cancer," Melisi stated. "The TAK-1 inhibitor used in this study is an exciting drug that warrants further development for the treatment of pancreatic cancer."

More information

The American Cancer Society has more about pancreatic cancer.



-- Robert Preidt



SOURCE: European Cancer Organization, news release, Sept. 24, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New Treatment May Beat Melanoma
2. Lifestyle interventions in the prevention and treatment of cancer
3. M. D. Anderson examines use of toad venom in cancer treatment
4. Michael J. Fox Foundation Commits Up to $5 Million to Help Advance Neurotrophic Factors From Promise to Reality As Parkinsons Treatment
5. Shady Grove Fertility Center Presents 5K Fundraising Race to Help Families Afford Fertility Treatment or Adoption
6. Study reveals 2/3 of prostate cancer patients do not need treatment
7. Discovery could improve hepatitis C treatment
8. Targeted heat therapy offers new standard treatment option for soft tissue sarcoma
9. National Autism Center Releases Groundbreaking Report on Autism Treatments
10. Women's Pelvic Organ Prolapse and Incontinence Guide Informs, Outlines Treatments
11. FDA Advisory Committee Unanimously Recommends Approval of XIAFLEX(TM) for Treatment of Dupuytrens Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Hope for Treatment of Pancreatic Cancer
(Date:2/23/2017)... CA (PRWEB) , ... February 23, 2017 , ... Hamlin ... to announce that they are sponsoring a raffle. Throughout the month of February, patients ... will receive a gift card for a dinner for two at the Cheesecake Factory. ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, 2017, ... “Doping in Sport: How the Culture Might Change,” in conjunction with ... symposium will be held at Pepperdine University in Malibu, California. , Sir Philip ...
(Date:2/23/2017)... PHILADELPHIA (PRWEB) , ... February 23, 2017 , ... ... risk and uncertainty in clinical trials, today announced that Premier Research, a leading ... management solution. , Clinical trials are becoming increasingly complex, due in part to ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... partnership with the Rhode Island Consortium for Autism Research and Treatment (RI-CART) and ... children with autism spectrum disorder (ASD) to see films in an environment that ...
(Date:2/23/2017)... Angeles, CA (PRWEB) , ... February 23, 2017 , ... ... her Smiling Patriot program today with a new Indiegogo campaign . ... care to homeless veterans in the Los Angeles area, either as a participating patient ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 Research ... Prosthetic Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 9.2% over the next ... industry report analyzes the market estimates and forecasts for all the ...
(Date:2/23/2017)... 23, 2017 MabVax Therapeutics Holdings, ... development company, announces that it has received notice ... authorizing the initiation a Phase I clinical trial ... cancer. MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is the Company,s ... to initiate the phase I clinical trial in ...
(Date:2/23/2017)... , Feb. 22, 2017 Orthopedic ... implant demand, as aging demographic patterns lead to ... Implants for sports- and exercise-related injuries, chronic back ... will lead sales gains. The future of medical ... addresses the following questions and more: - ...
Breaking Medicine Technology: